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Abstract 
Secretory Leukocyte Peptidase Inhibitor (SLPI) 
functionality in health and disease: Secretory 
Leukocyte Peptidase Inhibitor (SLPI) is a serine 
protease inhibitor of cathepsin G, trypsin and 
chymotrypsin, but primarily against neutrophil 
elastase. Its major function is to inhibit inflammation 
by blocking the proteolytic activity of these 
proteinases released by leukocytes and also through 
down-modulation of several cytokines. The anti-
inflammatory activity is also mediated by inhibition 
of the activation of the transcription nuclear factor 
NF-kB. Some studies localized the molecule within 
the cytosol and in secondary granules of neutrophils. 
Because of this, it is believed that neutrophil-derived 
SLPI may regulate the protease/antiprotease balance 
at sites of tissue inflammation. In relation with the 
adaptive immune system, it was suggested that SLPI 
modulates the cellular and humoral immune 
response, by decreasing the T cell proliferation and 
reducing the class switching. Also, it is known that 
this polycationic non-glycosylated peptide, displays 
anti-microbial properties against bacteria, viruses (in 
particular HIV) and fungus. In summary, the SLPI is 
a pleitropic molecule, implicated in physiological 
and pathological events, such as wound healing, 
pregnancy, chronic obstructive pulmonary disease, 
cancer, ischemia reperfusion injury and stroke, 
among others. Their detection in serum and 
biological fluids may be useful as a biomarker to 
diagnosis and prognosis for certain diseases. 
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Identity 
Other names: ALK1, ALP, HUSI, HUSI-I, BLPI, 
MPI, WAP4, WFDC4  
HGNC (Hugo): SLPI 
Location: 20q13.12 chr20:43,881,055- 43,883,184 
(reverse strand) 
DNA/RNA 
Description 
SLPI belongs to the whey acidic protein four-
disulfide core family of proteins. The human SLPI 
gene is localized on chromosome 20q12-13.2 
(Kikuchi et al. 1998). The SLPI gene consists of four 
exons and three introns, it spans approximately 2.6 
kb (Kikuchi et al. 1998; Stetler et al. 1986). The SLPI 
gene is stable and seems to be nonpolymorphic (Abe 
et al. 1991). Though, it has the potential to be 
modulated at both the transcriptional and post-
transcriptional levels (Abe et al. 1991). Up to date, it 
has not been detected a state of SLPI deficiency. 
However, patients with severe congenital 
neutropenia (a primary immunodeficiency syndrome 
characterized by mutations in at least 6 different 
genes) were found to have strongly reduced SLPI 
levels, being SLPI a key factor for the neutrophil 
differentiation in the bone marrow (Klimenkova et 
al. 2014). 
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Transcription 
The SLPI gene is actively transcribed in mucosal 
cells, being the half-life of the transcripts of 
approximately 12 h. Close to the exon 1, SLPI gene 
has four potential binding sites for transcription 
factor AP-1, three for AP-2 and one for 
C/EPB(Klimenkova et al. 2014). Also, Kikuchi et 
al., describes that SLPI has a promoter region which 
has a recognition sequence for two transcription 
factor, one of which is highly expressed in lung cell 
lines, and the other in nonlung cell lines (Kikuchi et 
al. 1997). 
Protein 
Description 
SLPI is an 11,7 kDa molecular weight non-
glycosylated protein composed by 132 amino acids 
(Stolk et al. 1999). The amino acid sequence of SLPI 
generates a highly polycationic peptide with two 
highly homologous domains. These two domains 
(COOH and NH2 terminal domains) share around a 
35% homology (Vogelmeier et al. 1996). Each 
domain contains eight cysteine residues that form 
four disulfide bonds, which helps to stabilize the 
structure of the molecule (Grutter et al. 1988). These 
cysteine rich domains are also called WAP domains 
(Whey Acid Protein). Domain 2 was initially 
described to bind and inhibit the serine proteases 
such as trypsin and elastase, while the domain 1 was 
probably not inhibitory (Eisenberg et al. 1990; 
Meckelein et al. 1990). It has been proposed that this 
last domain helps in the stabilization of the 
complexes "SLPI:elastase". Also, it is believed that 
the domain 1 mediates binding to heparin, and thus 
increases its antiprotease activity, probably as a 
result of a conformational change of the molecule 
(Faller et al. 1992). 
Expression 
SLPI was first isolated from bronchial secretions 
(Hochstrasser et al. 1972; Ohlsson et al. 1976). Then 
the SLPI was characterized by two groups of 
researchers, whom purified the molecule from the 
urine and (Seemuller et al. 1986) and the parotid 
gland secretions (Thompson et al. 1986). SLPI is 
located in both, the extracellular matrix and the 
intracellular compartments, suggesting that it could 
exert autocrine and paracrine effects (Taggart et al. 
2005).  
The expression of SLPI is constitutive as well as 
modulated by different factors. Constitutively SLPI 
can be found in serum and in extravascular mucosal 
fluids. Thus, it is found around of 40 (26.1-65.0) 
ng/ml in serum, 72 (0.4-250) ng/ml in bronchial 
lavage fluid (Hollander et al. 2007), in exhaled 
breath condensate (2.82 -  0.58 pg/ml) (Tateosian et 
al. 2012) and saliva (0.3-3.2 ug/ml) (Shugars et al. 
2001). However, concentrations of the molecule 
vary depending on age and gender of the individual 
tested.  In vivo, it is produced in the lung by tracheal 
serous glands and by clear bronchial cells. In male 
(Ohlsson et al. 1995) and female (Moriyama et al. 
1999) genital tracts, SLPI is located in seminal 
plasma and cervical mucosa, respectively. 
Furthermore, it is produced by the parotid glands, 
intestinal epithelial cells (Si-Tahar et al. 2000), renal 
tubule cells (Ohlsson et al. 2001), keratinocytes 
(Wiedow et al. 1998), beta cells of the pancreas 
(Nystrom et al. 1999) and immune cells like 
neutrophils and alveolar macropaghes (Sallenave et 
al. 1997; Mihaila et al. 2001; Guerrieri et al. 2011).  
The SLPI expression is modulated by different 
molecules. It has been shown that SLPI is up-
regulated by LPS, IL-1beta, TNF-alpha, neutrophil 
elastasa, alpha-defensins, surfactant protein A, 
corticosteroid and progesterone (Sallenave et al. 
1994; Reid et al. 1999; Maruyama et al. 1994; 
Abbinante-Nissen et al. 1995; King et al. 2003; 
Velarde et al. 2005; van Wetering et al. 2000; 
Ramadas et al. 2009). Finally, apoptotic cells can 
upregulate SLPI production by macrophages (Odaka 
et al. 2003).  
In contrast, few factors can downmodulate the 
expression of SLPI. Among them, the most 
significant are IFNgamma and TGF-beta (Jaumann 
et al. 2000; Jin et al. 1997).  
Although, the structure of SLPI seems to be stable, it 
could be cleaved and inactive-ated by 
chymase(Belkowski et al. 2008), cathepsins B, L, S 
(Taggart et al. 2001), lipid peroxidation products 
(Tomova et al. 1994) and Host dust mite 1 allergen 
(Brown et al. 2003), among others(Weldon et al. 
2009). 
Function 
Antiprotease activity:  The inhibition of protease 
activity was described for C-terminus domain 
against elastasa, cathepsin G, trypsin, chymotrypsin, 
tryptase and chymase (Williams et al. 2006). Thus, 
SLPI major function is inhibit inflammation by 
blocking the proteolytic activity of serine proteinases 
released by leukocytes and also through blocking the 
LPS effects, such as the upregulation of several 
cytokines like TNFalpha, MCP-1 and IL-6 (Yang et 
al. 2005; Jin et al. 1998; Taggart et al. 2005; Ashcroft 
et al. 2000). SLPI acts locally to maintain a 
protease/antiprotease balance thereby preventing 
protease mediated tissue destruction (Vogelmeier et 
al. 1990). In the lungs, the disturbance of this balance 
is responsible for various lung diseases, many of 
which are initiated and maintained by the 
recruitment and activation of neutrophils (Birrer et 
al. 1994; Suter 1989).  
Anti-inflammatory activity: SLPI has anti-
inflammatory activities not necessarily related to its 
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ability to inhibit extracellular proteases. The anti-
inflammatory activity is also mediated by inhibition 
of proteolytic degradation of IkB, an inhibitor of the 
nuclear factor NF-kB (Ashcroft et al. 2000; Samsom 
et al. 2007).  
It has been shown that over-expression of SLPI 
inhibits NF-kB, which is a transcription factor of 
several pro-inflammatory mediators in pulmonary 
inflammation (Henriksen et al. 2004). Currently, 
there are some evidence that SLPI is rapidly taken up 
by cells and is localized in the nucleus and cytoplasm 
(Taggart et al. 2002). In the cytoplasm, SLPI 
prevents degradation of several key proteins in the 
regulated activation of NF-kB, as IkBalpha, IkBbeta 
and IRAK (IL-1-receptor-associated kinase) through 
the ubiquitin-proteasome mechanism (Greene et al. 
2004; Taggart et al. 2002), that follows the activation 
of NF-kB by LPS or LTA (lipoteichoic acids). Also 
it has been proposed that SLPI acting in the nucleus 
can bind to NF-kB consensus region of target genes 
(Taggart et al. 2005). The entering into the nucleus 
occurs through a mechanism in which SLPI may 
traverse membranes, due to its cationic nature 
(favored by the high content of arginine and lysine) 
by interaction with the negatively charged 
membrane. Independently of the mode of action, in 
vivo experiments have demonstrated anti-
inflammatory / pro-apoptotic activities in the lung, 
and in a variety of other organs.  
Microbicidal activity:  
- Against Bacteria:   
SLPI displays anti-microbial properties in vivo and 
in vitro (Sallenave 2002; Gomez et al. 2009). It has 
been recently reported that mouse and even human 
SLPI shows anti-bacterial activity against 
mycobacteria and it constitutes a pattern recognition 
receptor (PRR), that not only kills the 
microorganism, but also facilitates their 
phagocytosis by murine and human macrophages 
(Nishimura et al. 2008; Gomez et al. 2009).  Either 
the antimicrobial activity or PRR ability depends on 
the COOH terminal domain where the inhibitory 
activity of serine proteases resides. The WAPs 
domains of the molecule are involved, and this is due 
to cationic residues that allow the disruption of the 
membranes of target organisms (Verma et al. 2007; 
Gomez et al. 2009; Nishimura et al. 2008). The 
antimicrobial activity of human SLPI has been 
described for various bacteria such as Pseudomonas 
aeruginosa, Staphylococcus aureus, Staphylococcus 
epidermis (Wiedow et al. 1998; Wingens et al. 
1998),  Mycobacterium tuberculosis (Gomez et al. 
2009), and Escherichia coli (Williams et al. 2006). 
Therefore this activity is against Gram negative and 
Gram positive bacteria and is part of the defense 
system of the mucosa.  
- Against Viruses:  
SLPI has been suggested as the main soluble factor 
responsible for the HIV inhibitory effect of saliva. It 
is well-established that human saliva inhibits HIV 
infectivity in vitro (McNeely et al. 1995; 
Nagashunmugam et al. 1997; Shugars et al. 2001; 
Malamud et al. 1992; Fultz 1986). The infection of 
adherent primary monocytes with HIV-1 was 
significantly suppressed in the presence of human 
saliva [76-80]. Four in vitro studies have 
demonstrated that SLPI has anti-HIV-1 activity in 
cells that included peripheral blood mononuclear 
cells, purified primary T cells, and SupT1 cells, a 
lymphocyte-derived tumor cell line (Fultz 1986; 
Hocini et al. 2000; Shugars et al. 1997; Skott et al. 
2002).  
Evidence suggests that SLPI blocks HIV-1 
internalization in a dose-dependent manner 
(McNeely et al. 1997). McNeely et al. found that 
SLPI inhibits a step of viral infection that occurs 
after virus binding but before reverse transcription. 
In a co-precipitation experiment, it was described a 
55-kDa cell surface protein from monocytes by 
using anti-SLPI antibodies. For some authors, the 
interaction between HIV and CCR5 could be the 
main target of SLPI (Naif et al. 1998). Other authors 
showed that SLPI interferes with HIV fusion with 
the T-cell plasma membrane through binding to 
scramblase 1, a membrane protein that interacts with 
CD4 and controls the movement of the phospholipid 
bilayer of the plasma membrane (Shugars et al. 
1999). It was also demonstrated that in myeloid cell, 
SLPI blocks viral entry/fusion as a result of binding 
to annexin II (Ohlsson et al. 2001; Ma et al. 2004; 
Drannik et al. 2011). This molecule is a macrophage 
receptor that binds to phosphatidylserine moiety that 
HIV carries on its outer layer on exiting from an 
infected cell (Ohlsson et al. 2001; Drannik et al. 
2011; Ma et al. 2004). Furthermore, the elastase 
inhibiting activity of SLPI was not be essential for 
their anti-HIV-1 activity (McNeely et al. 1997).  
- Against Fungi:  
C. albicans and Aspergillus fumigatus were sensitive 
to the antimicrobial activity of recombinant SLPI. 
This activity was localized to N-terminal domain of 
the molecule (Tomee et al. 1997).  
Wound healing activity: The role of SLPI in tissue 
repair was suggested by the observation that in 
human, epithelial expression of SLPI is increased in 
damaged skin (Wingens et al. 1998). Studies in SLPI 
deficient mice demonstrated that SLPI has an 
essential role in wound healing (Ashcroft et al. 
2000). In the absence of SLPI, the animals presents 
a delay in cutaneous wound healing, which is 
attributed to an increased and prolonged 
inflammatory response during the repair process, 
and a delay in the accumulation of the matrix. The 
altered inflammatory profile involves enhanced 
activation of local TGF-beta (Ashcroft et al. 2000).  
Immunomodulatory activity in adaptive immune 
response: The effect of SLPI seems not to be limited 
to innate immune response but also to the cellular 
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and humoral adaptive immune response. In fact, the 
high SLPI expression was found in dendritic cells of 
mucosal lymph node  and it was suggested that these 
dendritic cells regulate cellular activation to 
microbial products and maintain the tolerance 
threshold (Samsom et al. 2007).   
Also, we have observed that SLPI decreases 
lymphocyte proliferation, a phenomenon which 
depends on the presence of monocytes (Guerrieri et 
al. 2011).  However, it is not possible to rule out a 
direct effect of SLPI on lymphocytes since it is able 
to bind the receptors phospholipid scramblases 1 and 
4 on CD4 T cells (Py et al. 2009). On tonsillar cells, 
SLPI inhibits B cells expressing activation-induced 
cytidine deaminase, an enzyme involved in class 
switching.  
Thus, the overall idea is that SLPI is a tolerigenic 
factor, that it is able to down modulate the innate and 
adaptive immune response. Moreover, recently it has 
been shown that the hyporesponsiveness of human 
buccal epithelium to microbial stimulation is a 
phenomenon that depends on SLPI expression. 
(Menckeberg et al. 2015).  
Recently, it has been also described that SLPI, in 
conjunction of neutrophil DNA or cathepsin G and 
human neutrophil elastase, induced a marked 
production of type I interferon by plasmacytoid 
dendritic cells (Skrzeczynska-Moncznik et al. 2012; 
Skrzeczynska-Moncznik et al. 2013).  
On the other hand, it was found that SLPI inhibits the 
formation of neutrophil extracellular traps; 
structures that are involved in the elimination of 
microorganisms, and also in the presentation of 
autoantigens (Zabieglo et al. 2015). These findings 
suggest a role of SLPI in autoimmune diseases. 
Implicated in 
Cancer 
The invasiveness of tumors occurs through 
infiltration of tumor cells into healthy tissue and by 
angiogenesis, which is modulated by proteases and 
antiproteases released from tumor cells that carry out 
tissue remodeling.  
Many studies have shown that SLPI expression is 
modulated in cancer. However, there has been 
reported an increased or decreased expression profile 
of the protein depending on the type of tumor.  
For example, SLPI expression is increased in 
pancreatic (Iacobuzio-Donahue et al. 2003), thyroid 
(Jarzab et al. 2005), cervix (Rein et al. 2004), 
endometrial (Zhang et al. 2002), ovarian (Israeli et 
al. 2005) and gastric cancer (Cheng et al. 2008).  
In contrast, it is weakly expressed in nasopharyngeal 
carcinoma (Sriuranpong et al. 2004; Huang et al. 
2012), bladder tumors (Liang et al. 2002) and some 
breast carcinomas (Hu et al. 2004). As we mentioned 
above, in ovarian cancer, SLPI is over-expressed and 
is thought to have a carcinogenic function (Hough et 
al. 2001; Clauss et al. 2005; Devoogdt et al. 2009) 
independent of its antiprotease activity (Simpkins et 
al. 2008). However, in Lewis lung cancer cells, the 
pro-tumoral activity was shown to be dependent on 
its protease inhibitor activity (Devoogdt et al. 2003). 
Also, it was described that SLPI plasma levels were 
elevated in lung cancer patients (Zelvyte et al. 2004). 
More recently, low level of SLPI was detected in oral 
squamous cell carcinoma compared with normal oral 
epithelium (Wen et al. 2011). Moreover, an inverse 
correlation was also reported between SLPI and 
histological parameters associated with tumor 
progression (Wen et al. 2011). Interestingly, SLPI 
reduced the hepatic lung carcinoma metastasis 
(Wang et al. 2006). In breast tumors, the mRNA 
expression of SLPI either increases or decreases 
depending on the case (Kluger et al. 2004; Stoff-
Khalili et al. 2005). Also in a breast tumor cell line, 
the SLPI overexpressing cells did not develop 
tumors in mice (Amiano et al. 2013). This effect was 
specific for this type of cell line, since colon tumor 
cells overexpressing SLPI, developed faster tumors 
than control cells. Moreover, the breast cancer cell 
line that overexpresses SLPI showed a decrease in E-
cadherin expression, pro-apoptotic effects and cell 
cycle arrests. (Rosso et al. 2014). Interestingly, the 
administration of these SLPI transfected cells, which 
do not develop tumor in immunocompetent mice, 
inhibited the tumor growth and increased the 
survival of mice that were inoculated with mock 
transfected control cells. (Amiano et al. 2011).  
In ovarian cancer SLPI inhibits cell growth through 
an apoptotic pathway (Nakamura et al. 2008), while, 
it has been also described that over-expression of 
SLPI is capable of producing a more aggressive 
ovarian cancer in vitro and in vivo models 
(Devoogdt et al. 2009). In fact, it was suggested that 
SLPI could be a useful diagnostic and prognostic 
tool in ovarian cancer (Carlson et al. 2013).  
The SLPI gene and the protein expression are 
significantly lower in metastatic "head and neck 
squamous cell carcinoma" compared with non-
metastatic ones. Also, an inverse significant 
correlation with HPV status was found for this kind 
of tumor (Hoffmann et al. 2013). Therefore, overall 
these data suggests us that it is not possible to 
generalize the findings related to SLPI expression 
and function in only a unique type of tumor, since its 
expression and modulation seems to be tumor 
specific. 
Pregnancy 
SLPI among others antimicrobial peptides seems to 
play a role in pregnancy. SLPI is produced by 
amnion epithelium and deciduas (King et al. 2007). 
High levels of SLPI were found in the cervical 
mucus plug during human pregnancy. The SLPI 
mRNA expression was higher in the second and the 
third trimester when compared with the first one 
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(Itaoka et al. 2015). Thus, in amniotic fluid, its 
concentration increases according to the period of 
pregnancy and the highest levels is reached on the 
onset of labor (Denison et al. 1999). As SLPI is a 
natural antimicrobial molecule, it may be involved in 
the prevention of uterine infection during pregnancy 
and labor, and be a modulator of inflammation in this 
stage. 
Autoimmunity 
High levels of SLPI have been observed in several 
autoimmune diseases. For example, it was observed 
in: i) inflamed joint tissues in a rat model of arthritis 
(Song et al. 1999); ii) patients with primary Sjögren's 
syndrome (Maruyama et al. 1998); iii) immune cells 
infiltrating the corpus in autoimmune gastritis (Hritz 
et al. 2006); iv) macrophages, activated microglia, 
neuronal cells and astrocytes during experimental 
autoimmune encephalomyelitis (Mueller et al. 
2008).  
In contrast, the administration of systemic SLPI or 
microencapsulated SLPI has proven to reduce the 
injury found in tissues of different autoimmune 
models (Guazzone et al. 2011; Song et al. 1999). 
Overall, these results highlight the in vivo 
immunosuppressive effect of SLPI. However, it has 
been also implicated in the pathogenesis of other 
autoimmune diseases such as psoriasis. As we 
mentioned above, Nestle et al. have demonstrated 
that the IFNalpha, produced by plasmacytoid 
dendritic cells in response to DNA structures, 
containing the neutrophil serine protease cathepsin G 
(CatG) and SLPI was important in the development 
of psoriatic skin lesions (Skrzeczynska-Moncznik et 
al. 2013). In fact, the neutralization of SLPI reduces 
the severity of experimental autoimmune 
encephalitis (Muller et al. 2012). 
Tuberculosis 
Exposure of murine peritoneal macrophages to 
Mycobacterium tuberculosis led to an increase in 
SLPI protein secretion (Ding et al. 2005) which 
seems to be a pattern recognition receptor for 
micobacterias and inhibits the growth of 
them(Nishimura et al. 2008; Gomez et al. 2009). In 
plasma of tuberculosis patients, the SLPI and IFN-
gamma levels were significantly higher compared 
with the levels found in healthy subjects. Moreover, 
a direct association between SLPI levels and the 
severity of tuberculosis was detected. The main 
protective cytokine in tuberculosis, IFN-gamma, 
decreased the expression of SLPI in healthy subjects 
but not in tuberculosis patients, probably because of 
the low expression of IFN- gammaR detected in 
these patients (Tateosian et al. 2014). 
Chronic obstructive pulmonary 
disease (COPD) 
Emphysema may be due to an imbalance in protease-
antiprotease activity. Patients with COPD show high 
levels of SLPI compared with healthy subjects 
(Hollander et al. 2007). Conversely, SLPI levels are 
decreased during COPD exacerbations produced by 
bacterial infection or rhinovirus (Mallia et al. 2012). 
Ischemia reperfusion injury 
It has been described a protective effect of SLPI in 
different ischemia/reperfusion injury models, such 
as heart and liver (Amberger et al. 2002; Lentsch et 
al. 1999). We have also observed a beneficial effect 
of SLPI in kidney ischemia reperfusion injury 
(unpublished result). Interestingly, in cardiac 
transplantation, null mice for SLPI had an impaired 
function after cold ischemia unlike the wild type 
(Schneeberger et al. 2008). Moreover, when SLPI 
was added to the preservation solution, myocardial 
contraction was restored to normal. 
Central Nervous System Ischemia 
In two rat models, one of focal cerebral ischemia 
(Wang et al. 2003) and the other of spinal injury, it 
was observed high levels of SLPI. The same was 
seen in ischemic stroke in humans (Ilzecka et al. 
2002). Interestingly, the administration of SLPI has 
been shown to be neuroprotective in both models of 
injury in rats (Wang et al. 2003; Hannila et al. 2013). 
Taking into account that the  SLPI can promote 
axonal regeneration, plus the evidence of their 
neuroprotective effects, we could consider this 
molecule as potential therapeutic tool for different 
nervous system diseases (Hannila 2014). 
Biomarker 
It has been found that the determination of serum 
SLPI levels could be useful as a marker of several 
diseases, such as disease activity in systemic 
sclerosis with interstitial lung disease (Aozasa et al. 
2012). Also, it has been suggested that a form of 
cleaved SLPI can reflect the disease activity of 
patients with allergic rhinitis and asthma (Belkowski 
et al. 2009). It was also been proposed as a biomarker 
in ovarian and gastric cancer (Devoogdt et al. 2009; 
Cheng et al. 2008), or to identify subjects at risk of 
infections and malignant transformation due to HIV 
infection (Nittayananta et al. 2013). Recently, it was 
proposed as a biomarker for acute kidney injury after 
transplantation (Wilflingseder et al. 2014). However, 
until now none of these assays have been introduced 
in the clinical settings. 
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